2015 BIO International Convention Super Sessions Announced
Washington, D.C. (March 31, 2015) – The 2015 BIO International Convention® will feature Super Sessions focusing on industry analysis, forecasts and discussions on hot topics. The Convention, hosted by the Biotechnology Industry Organization (BIO), is the global event for biotechnology – and will take place June 15-18, 2015 at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.
“BIO is proud to host the industry’s top executives to share perspectives on major trends that will impact the future of global healthcare,” said Scott Whitaker, President of the BIO International Convention. “Year over year, attendees have come to expect dynamic speakers engaged in compelling conversations with key takeaways to apply to their everyday business practices. This year’s speakers will not disappoint.”
2015 Super Sessions include:
Ensuring Patient Access to Innovative Medicines
Since passage of the Affordable Care Act in 2010, the health insurance landscape in the U.S. has changed significantly. The resulting changes in insurance marketplaces and in Medicare mean that more Americans have access to health insurance — but does access translate to quality healthcare? The panel will identify the root of these access challenges and discuss potential policy implications in addressing these challenges.
Sponsored by: Novartis Pharmaceuticals Corporation
Tuesday, June 16, 10:00 – 11:30 AM
- Moderator: Christi Shaw, US Country Head, President, Novartis Corporation and President of Novartis Pharmaceuticals Corporation
- Speakers: Randy Beranek, President & CEO, National Psoriasis Foundation, Arthur Caplan, PhD, Director, Division of Medical Ethics, New York University Langone Medical Center; and Richard Pops, Chairman and Chief Executive Officer, Alkermes, Inc.
M&A and Capital Allocation: Everything Old is New Again
Over the last 18 months, our industry has witnessed unprecedented transaction activity driven by rising confidence in pipelines, more focused growth strategies and rational capital allocation. This panel brings together CEOs and other senior leaders with firsthand experience navigating the deal landscape while balancing the often conflicting demands of investors, patients, employees and regulators. The panel will be supplemented with fresh data from recent Ernst & Young (EY) research on M&A statistics, firepower and activism.
Sponsored by: EY
Tuesday, June 16, 2:00 – 3:30 PM
- Moderators: Glen Giovannetti, Global Life Sciences Leaders, EY and Jeffrey Greene, Global Transactions Leader, Life Sciences, EY
- Speakers: Geno Germano, Group President, Global Innovative Pharma Business, Pfizer and David Pyott, Former Chairman of the Board and Chief Executive Officer (1998-2015), Allergan
Investment Incentives to Combat Antimicrobial Resistance (AMR)
Globally, antimicrobial resistance has become one of the most significant public health issues, affecting all countries and causing increasing hospitalizations, extended illness, and escalating healthcare costs. Panelists will discuss various global initiatives and what incentives will best encourage industry R&D.
Sponsored by: Merck
Wednesday, June 17, 10:00 – 11:30 AM
- Speakers: Julie Gerberding, MD, Executive Vice President, Strategic Communications, Global Public Policy, and Population Health, Merck & Co Inc
- Kenneth J. Hillan, Chief Executive Officer, Achaogen
Accelerating Innovation in the 21st Century
Policymakers and regulators in the United States and Europe are increasingly considering how best to ensure promising scientific research is effectively and quickly translated into new therapies for patients. In the United States, new regulatory pathways have been introduced and bi-partisan Congressional legislation, aimed at accelerating innovation, is in the process of being developed through the 21st Century Cures Initiative. The United Kingdom/Europe is seeking to accelerate innovation through, among other things, the Innovative Medicines Initiative and adaptive licensing. Panel participants will have a robust policy discussion that considers some of the challenges, identifies what has worked well, and looks forward to continue to deliver on the promise of innovation.
Sponsored by: AstraZeneca
Wednesday, June 17, 2:00 – 3:30 PM
- Moderator: Paul Hudson, President, AstraZeneca US and Executive Vice President, North America, AstraZeneca
Riding the Bull Market: What’s in Store for Biotech Dealmakers in 2015?
Campbell Alliance and BIO are pleased to present updated findings from two unique and forward-looking measures of deal-making in the industry – the Campbell Alliance Dealmakers’ Intentions Study and the BIO One-on-One Partnering Forecast. Based on a survey of more than 150 industry executives and business development professionals, Dealmakers’ Intentions provides insight into what will likely drive the industry’s partnering and M&A efforts moving forward, and the implications for deal-making over the next year or more.
A highly distinguished panel of dealmakers will then explore the impact these market forces will have on pharmaceutical and biotech companies as they strive to make that next big deal.
Sponsored by: Campbell Alliance
Thursday, June 18, 10:00 – 11:30 AM
- Moderators: Sougato Das, Director, Partnering, Biotechnology Industry Organization and Neel Patel, Director, Corporate Development, Campbell Alliance
- Speaker: David H. Donabedian, Ph.D, Vice President, Head of Ventures & Early Stage Collaborations, AbbVie Inc.
The Next Step:
How Companies Build Successful Therapeutic Franchises from the Ground Up
Whether you’re an established commercial entity or an emerging biotech company that is commercializing for the first time, building a franchise in a new therapeutic area from the ground up raises a host of questions: how much risk should be accepted, how quickly, and how large, should a salesforce be built, what capabilities are needed, and is a partner needed to fully leverage the opportunity. It is known that your first moves into a new therapeutic area are critical and that your first year on the market will likely dictate the product’s success. Panelists will provide real life examples of what it takes to build a therapeutic franchise through a moderated panel discussion.
Thursday, June 18, 12:00 – 1:30 PM
Sponsored by: EMD Serono, Inc.
What is happening in biotechnology and life science development on the global stage? Which issues will bring all nations together in the future? As the world continues to flatten, individual countries are finding new ways to grow the industry, and in some cases, doing it better than the US. Panelists at this year’s annual SCIENTIFIC AMERICAN Worldview will examine the future of global innovation in a lively conversation.
Thursday, June 18, 2:00 – 3:30 PM
- Moderator: David Brancaccio, Host, American Public Media’s Marketplace Morning Report
To learn more about the event and available registration packages, please visit convention.bio.org/register.
Advance media registration is now available for qualified reporters working full time for print, broadcast and web publications with valid press credentials. To register, please visit here.